Vemurafenib in Chinese patients with BRAFV600 mutation–positive unresectable or metastatic melanoma: an open-label, multicenter phase I study

被引：0
|
作者：
Lu Si
Xiaoshi Zhang
Zhen Xu
Qiudi Jiang
Lilian Bu
Xuan Wang
Lili Mao
Weijiang Zhang
Nicole Richie
Jun Guo
机构：
[1] Peking University Cancer Hospital & Institute,Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education)
[2] Sun Yat-sen University Cancer Center,undefined
[3] Roche Product Development in Asia Pacific,undefined
[4] Roche R&D Center China Ltd.,undefined
[5] Roche Innovation Center New York,undefined
[6] Genentech,undefined
[7] Inc.,undefined
来源：
BMC Cancer | / 18卷
关键词：
-positive; Advanced melanoma; Vemurafenib; China; Asia;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] An imaging study of vemurafenib in patients with BRAFV600-mutated metastatic melanoma.
    Lastoria, Secondo
    Grimaldi, Antonio M.
    Aloj, Luigi
    Simeone, Ester
    Romano, Anna
    Caraco, Corradina
    Curvietto, Marcello
    Esposito, Assunta
    Caraco, Corrado
    Mozzillo, Nicola
    Torri, Valter
    Ascierto, Paolo Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [42] Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study
    Mao, Lili
    Fang, Meiyu
    Chen, Yu
    Wei, Xiaoting
    Cao, Jun
    Lin, Jing
    Zhang, Peng
    Chen, Ling
    Cao, Xiao
    Chen, Yujun
    Guo, Jun
    Si, Lu
    CLINICAL CANCER RESEARCH, 2022, 28 (21) : 4642 - 4648
  • [43] A phase I, open-label study of pasireotide in patients with BRAF-and NRAS-wild type, unresectable and or metastatic melanoma
    Dummer, R.
    Michielin, O. A.
    Nageli, M.
    Goldinger, S. M.
    Campigotto, F.
    Kriemler-Krahn, U.
    Schmid, H.
    Pedroncelli, A.
    Micaletto, S.
    Schadendorf, D.
    ANNALS OF ONCOLOGY, 2016, 27
  • [44] A prospective observational safety study of patients with BRAFV600-mutated unresectable or metastatic melanoma treated with vemurafenib (Zelboraf Safety Study)
    Corrie, P. G.
    Terheyden, P.
    ten Tije, A. J.
    Herbst, R.
    Jansen, R.
    Marples, M.
    Debus, D.
    Marconcini, R.
    Blasinska-Morawiec, M.
    Freivogel, K.
    Munson, M. L. G.
    Goodman, G. R.
    Hsu, J. J.
    Sadetsky, N.
    Colburn, D.
    Rutkowski, P.
    BRITISH JOURNAL OF DERMATOLOGY, 2019, 180 (05) : 1254 - 1255
  • [45] VEMURAFENIB AND COBIMETINIB POTENTLY INHIBIT PS6 SIGNALING IN BRAFV600 MUTATION-POSITIVE LOCALLY ADVANCED OR METASTATIC MELANOMA FROM BRIM7 STUDY
    Yan, Y.
    McArthur, G.
    Gajewski, T.
    Puzanov, I.
    Hamid, O.
    Gonzalez, R.
    Wang, Y.
    Lu, S.
    Wongchenko, M.
    Choong, N. W.
    Ribas, A.
    ANNALS OF ONCOLOGY, 2014, 25
  • [46] An open-label, multicenter safety study of vemurafenib (PLX4032, RO5185426) in patients with metastatic melanoma.
    Larkin, James M. G.
    Queirolo, Paola
    Arance, Ana M.
    Brown, Michael Paul
    Hauschild, Axel
    Del Vecchio, Michele
    McArthur, Grant A.
    Neyns, Bart
    Becker, Juergen C.
    Hansson, Johan
    Hogg, David
    Antonio Ascierto, Paolo
    Loquai, Carmen
    Espinosa, Enrique
    Garbe, Claus
    Patel, Poulam M.
    Schachter, Jacob
    Mitchell, Lada
    Luisa Veronese, Maria
    Blank, Christian U.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [47] Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study
    McArthur, G. A.
    Maio, M.
    Arance, A.
    Nathan, P.
    Blank, C.
    Avril, M. -F.
    Garbe, C.
    Hauschild, A.
    Schadendorf, D.
    Hamid, O.
    Fluck, M.
    Thebeau, M.
    Schachter, J.
    Kefford, R.
    Chamberlain, M.
    Makrutzki, M.
    Robson, S.
    Gonzalez, R.
    Margolin, K.
    ANNALS OF ONCOLOGY, 2017, 28 (03) : 634 - 641
  • [48] Atezolizumab plus bevacizumab in patients with unresectable or metastatic mucosal melanoma: A multicenter, open-label, single-arm phase 2 study.
    Mao, Lili
    Fang, Meiyu
    Chen, Yu
    Bai, Xue
    Cao, Jun
    Lin, Jing
    Zhang, Peng
    Chen, Ling
    Xu, Jiahui
    Guo, Jun
    Si, Lu
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [49] An open-label pilot study of vemurafenib in previously treated metastatic melanoma patients with brain metastases.
    Dummer, R.
    Rinderknecht, J.
    Goldinger, S. M.
    Wagner, I.
    Mitchell, L.
    Veronese, M. L.
    Nick, S.
    Hilfiker, P.
    Gobbi, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [50] Survival in adult patients with BRAFV600 mutation-positive advanced melanoma: a noninterventional ambispective study of patients with cobimetinib combined with vemurafenib during the French early access program: MELANIS study
    Meyer, Nicolas
    Perol, David
    Duval-Modeste, Anne-Benedicte
    El Adaoui, Laila
    Lelarge, Yoann
    Niarra, Ralph
    Mateus, Christine
    MELANOMA RESEARCH, 2022, 32 (04) : 269 - 277
12345